Allergic Reactions to Currently Available COVID-19 Vaccination
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 July 2024 | Viewed by 139
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue of Vaccines focuses on allergic reactions caused by existing COVID-19 vaccines.
We invite you to contribute an original research article, review or perspective on the latest research to highlight: (1) allergic reactions to vaccines on the market; (2) their causes; (3) future vaccines; and (4) information available and decision-making among individuals who hesitate to be vaccinated because of possible allergic reactions.
Most immediate-type hypersensitivity reactions, generally IgE-mediated, are the result of the degranulation of mast cells. Other reactions, including vasovagal reactions and anxiety-related symptoms, mimic anaphylaxis. To date, no IgE-mediated mechanism has been conclusively demonstrated, but a complement activation-related pseudoallergy (CARPA) has been theorized. Other immediate and late local systemic reactions also exist.
The first two vaccines, both mRNA vaccines, have been used, with certain alterations. Initially, several cases of anaphylaxis, as defined by the Brighton Collaboration, were presented. Polyethylenglycol (PEG), and subsequently its derivatives, were suspected. Upon researching and evaluating the reactions, fewer adverse reactions were described. In many cases, patients with a systemic oral ingestion of drugs containing PEG 3350 experienced no anaphylaxis related to the mRNA vaccines with PEG.
We look forward to receiving your contributions.
Prof. Dr. Lennart J. Nilsson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
